Loading clinical trials...
Loading clinical trials...
Phase 1 Study of Mogamulizumab (KW-0761) in Combination With MEDI4736 (Durvalumab) and Mogamulizumab in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
Conditions
Interventions
mogamulizumab
MEDI4736 (Durvalumab)
+1 more
Locations
7
United States
The Angeles Clinic
Los Angeles, California, United States
UCLA Hematology & Oncology Clinic
Los Angeles, California, United States
Yale Cancer Center
New Haven, Connecticut, United States
H. Lee Moffitt Cancer Center
Tampa, Florida, United States
Georgia Cancer Center
Augusta, Georgia, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Start Date
November 26, 2014
Primary Completion Date
December 8, 2017
Completion Date
March 5, 2018
Last Updated
April 25, 2024
NCT06898450
NCT05719558
NCT07029399
NCT04826341
NCT06819735
NCT06760819
Lead Sponsor
Kyowa Kirin, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions